Xlife Sciences AG Share Price BOERSE MUENCHEN
Equities
XLS
CH0461929603
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.8 EUR | -0.48% | -7.52% | -3.69% |
23/04 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
29/02 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 800K 875K 818K 73.03M | Sales 2025 * | - | Capitalization | 196M 214M 200M 17.86B |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.37M -4.09M -365M | Net income 2025 * | - | EV / Sales 2024 * | 326 x |
Net Debt 2024 * | 65.2M 71.29M 66.67M 5.95B | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-52
x | P/E ratio 2025 * |
-
| Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.77% |
1 day | -0.48% | ||
Current month | -3.69% | ||
Current year | -3.69% |
Managers | Title | Age | Since |
---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 01/19/01 |
Carl von Halem
DFI | Director of Finance/CFO | - | 01/21/01 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 12/19/12 |
Mark Müller
BRD | Director/Board Member | - | 25/18/25 |
Oliver Baumann
CEO | Chief Executive Officer | - | 01/19/01 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- XLS Stock
- XLS Stock